Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer

Clinical Cancer Research

Volumn 18, Issue 24, 2012, Pages 6748-6757

  Adams, Sylvia ^a   Kozhaya, Lina ^a   Martiniuk, Frank ^a   Meng, Tze Chiang ^b   Chiriboga, Luis ^a   Liebes, Leonard ^a   Hochman, Tsivia ^a   Shuman, Nicholas ^a   Axelrod, Deborah ^a   Speyer, James ^a   Novik, Yelena ^a   Tiersten, Amy ^a   Goldberg, Judith D ^a   Formenti, Silvia C ^a   Bhardwaj, Nina ^a   Unutmaz, Derya ^a   Demaria, Sandra ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b T Meng Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; CYTOKINE; IMIQUIMOD; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APPLICATION SITE DESQUAMATION; APPLICATION SITE INFECTION; APPLICATION SITE PAIN; APPLICATION SITE REACTION; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CARCINOGENESIS; CHILL; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DEHYDRATION; DEPRESSION; DERMATITIS; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEMALE; HUMAN; HYPERTHERMIA; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; LYMPHADENOPATHY; LYMPHOCYTIC INFILTRATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUNCH BIOPSY; SKIN BURNING SENSATION; SKIN INFECTION; SKIN METASTASIS; SKIN PAIN; SKIN PRURITUS; SKIN REDNESS; SKIN ULCER; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR REJECTION; VOMITING;

ADMINISTRATION, TOPICAL; ADULT; AGED; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYTOKINES; FEMALE; HUMANS; MIDDLE AGED; SKIN NEOPLASMS; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 7; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84871217036     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1149     Document Type: Article

References (35)

1. Krathen RA, Orengo IF, Rosen T. Cutaneous metastasis: a meta-analysis of data. South Med J 2003;96:164-7. (Pubitemid 36268589)
2. Lookingbill DP, Spangler N, Helm KF. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol 1993;29:228-36. (Pubitemid 23221903)
3. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol 2002;3:196-200. (Pubitemid 34141451)
4. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004;16:3-9. (Pubitemid 38147427)
5. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008;222:357-68. (Pubitemid 351430366)
6. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy 2009;1:949-64.
7. Panelli MC, Stashower ME, Slade HB, Smith K, Norwood C, Abati A, et al. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2007;8:R8.
8. Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008;27:190-9.
9. Hengge UR, Roth S, Tannapfel A. Topical imiquimod to treat recurrent breast cancer. Breast Cancer Res Treat 2005;94:93-4. (Pubitemid 41416946)
10. Heber G, Helbig D, Ponitzsch I, Wetzig T, Harth W, Simon JC. Complete remission of cutaneous and subcutaneous melanoma metastases of the scalp with imiquimod therapy. J Dtsch Dermatol Ges 2009;7:534-6.
11. Harrison LI, Skinner SL, Marbury TC, Owens ML, Kurup S, McKane S, et al. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol Res 2004;296:6-11. (Pubitemid 38828417)
12. Del Rosso JQ, Sofen H, Leshin B, Meng T, Kulp J, Levy S. Safety and efficacy of multiple 16-week courses of topical imiquimod for the treatment of large areas of skin involved with actinic keratoses. J Clin Aesthet Dermatol 2009;2:20-8.
13. Kouloulias VE, Dardoufas CE, Kouvaris JR, Gennatas CS, Polyzos AK, Gogas HJ, et al. Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I/II trial. Clin Cancer Res 2002;8:374-82. (Pubitemid 34193953)
14. Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002;20:3703-18. (Pubitemid 34983231)
15. Narayan R, Nguyen H, Bentow JJ, Moy L, Lee DK, Greger S, et al. Immunomodulation by imiquimod in patients with high-risk primary melanoma. J Invest Dermatol 2012;132:163-9.
16. Wenzel J, Uerlich M, Haller O, Bieber T, Tueting T. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. J Cutan Pathol 2005;32:257-62. (Pubitemid 40459926)
17. Clark RA, Huang SJ, Murphy GF, Mollet IG, Hijnen D, Muthukuru M, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med 2008;205:2221-34.
18. Schon M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003;95:1138-49. (Pubitemid 37045392)
19. Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 2012;122:575-85.
20. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007;204:1441-51. (Pubitemid 46919881)
21. Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008;181:776-84.
22. Gupta R, Babb JS, Singh B, Chiriboga L, Liebes L, Adams S, et al. The numbers of FoxP3+ lymphocytes in sentinel lymph nodes of breast cancer patients correlate with primary tumor size but not nodal status. Cancer Invest 2011;29:419-25.
23. Schott E, Witt H, Neumann K, Bergk A, Halangk J, Weich V, et al. Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-a-based therapy. J Viral Hepat 2008;15:71-8. (Pubitemid 350243584)
24. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancerchemotherapy and radiotherapy. NatMed2007;13:1050-9. (Pubitemid 47517504)
25. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28:4594-600.
26. Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther 2010;10:983-91.
27. Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004;10:5316-26. (Pubitemid 39100466)
28. Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 2005;11:4430-6. (Pubitemid 40825633)
29. Radfar S, Wang Y, Khong HT. Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo. J Immunol 2009;183:6800-7.
30. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12:1260-9. (Pubitemid 43342517)
31. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010;10:170-81.
32. Bogunovic D, Manches O, Godefroy E, Yewdall A, Gallois A, Salazar AM, et al. TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res 2011;71:5467-76.
33. Lu H, Wagner WM, Gad E, Yang Y, Duan H, Amon LM, et al. Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol 2010;184:5360-7.
34. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005;11:728-34. (Pubitemid 40116901)
35. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009;10:718-26.